Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
BRITTLEBONEDISORDERSCONSORTIUM Issue11
The Brittle Bone Disorders Consortium (BBDC) is a group of physicians, researchers, and educators dedicated to learning more about Osteogenesis Imperfecta (OI).We aim to develop new treatments and to improve the overall care of patients with OI by connecting patients with support groups, expert doctors, and clinical research opportunities.
Summer
2016 Newsletter
BBDCPARTICIPATINGCENTERS
WelcometotheBrittleBoneDisordersConsortium’s(BBDC)1stnewsletter.Itismyhopethatthisnewsletterwillkeepyouupdatedontheresearchthattheconsortiumisplanningforthecomingyears.TheBBDCisaconsortiumwithintheRareDiseaseNetworkestablishedbytheOfficeofRareDiseasesResearch,NCATS.WeareagroupofresearchersacrosstheUnitedStatesandCanadainterestedinlearningmoreaboutOsteogenesisImperfecta(OI).TheBBDCcurrentlyhas9participatingclinicalsitesand1datamanagementsite.WearealsoproudthattheOsteogenesisImperfectaFoundationisaparticipatingadvocacysitewithleadershipintrainingandeducation.OurpartnershipwiththeOsteogenesisImperfectaFoundationandallofthefamilieswithOIisacriticalcomponentofourmission.ThroughthesupportoftheOIFoundationsupportedLinkedClinicalResearchCenters(LCRC)andyourparticipation,wewereabletogatherimportantinformationaboutindividualslivingwithOIandformthefoundationonwhichtheBBDCwasbuilt.WhiletheLCRCnolongerexists,withitsmissionnowsupersededbytheBBDC,wearenow
positionedtoanswermanyimportantquestionsaboutthenaturalhistoryofOIandimprovedapproachestotreatOI.Infuturenewsletters,wewillupdateyouonspecificprojectsandinformyouabouthowtobestparticipate.
Nowalittleaboutme!Iamaphysicianandscientistwhohasstudiedgeneticsofbonediseasesforover25years.IhavebeenproudtohavecaredformanyofyouoryourfamilymembersaspartoftheSkeletalDysplasiaClinicatTexasChildren’sHospitalandBaylorCollegeofMedicine.OurcurrentresearchisfocusedonidentifyingnewgeneticcausesofOI,developingbetterteststodistinguishOItypeandpotentialresponsetotreatment,andcommonmechanismsthatcausebrittleboneastargetsfornewtreatments.Forexample,wehaveplanstotestadrugthatmaybeusefulinthetreatmentofsevereformsofOI.Ultimately,wehopethatourresearchwillallowphysicianstobettercareforindividualslivingwithOI.
Ourresearchisonlymeaningfulifwearepartnerstogether.Pleasestayincontactwithus,stayinformed,andletusknowwhatisimportanttoyouandyourfamilies.Yourneedsandideaswilltodriveourefforts.Ourteamlooksforwardtoseeingyouatoneofourparticipatingclinicalsites.
Brendan Lee, M.D., Ph.D.Chairman, Department of Molecular and Human Genetics
Clinical Sites Baylor College of Medicine Principal Investigator: V. Reid Sutton, M.D. Children’s National Medical Center Principal Investigator: Laura Tosi, M.D. Hospital for Special Surgery Principal Investigator: Cathleen Raggio M.D. Kennedy Krieger Institute / Hugo W. Moser Research Institute Principal Investigator: Emily Germain-Lee, M.D. Shriners Hospital for Children, Chicago / Marquette University Principal Investigator: Peter Smith, M.D. �Co-PI: Gerald Harris, PhD, PEShriners Hospital for Children, Montreal Principal Investigator: Frank Rauch, M.D. Oregon Health and Science University Principal Investigator: Eric Orwoll, M.D. University of California Los Angeles Principal Investigator: Deborah Krakow, M.D. University of Nebraska Medical Center with Children’s Hospital & Medical Center Principal Investigator: Eric Rush, M.D. Patient Advocacy Partner Osteogenesis Imperfecta Foundation: Principal Investigator: Tracy Hart, C.E.O. Cores University of South Florida Principal Investigator: Jeff Krischer Ph.D. University of Washington Principal Investigator: David Eyre Ph.D.
The Brittle Bone Disorders Consortium (U54 AR 068069) is part of the Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Disease Research (ORDR), NCATS, and is funded through collaboration between NCATS, and the National Institute of Dental and Craniofacial Research (NIDCR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Dr.BrendanLee
Welcome Message From Consortium PI, Brendan Lee, M.D.
TITLESUBTITLE|Issue1 2
TheLongitudinalStudyofOIopenedforenrollmentAugust2015.Our1stparticipantwouldliketoshareafewwords.
Q&A
Q:Tellusabitaboutyourself.A:MynameisAndersson,Iam15andin9thgradeatXavierAcademy.Ienjoymaththemost.ButwhenI'mnotatschoolIliketoplayvideogamesandIwritealot.I'mworkingonasequeltoabookIwroteafewyearsago.Q:Whatdoyouaspiretobeinthefuture?A:I'dliketobeanauthororsomethingtodowithanimals.Q:Youwerethe1stparticipantintheLinkedClinicalResearchCentersstudyandthe1stparticipantinTheBrittleBoneDisordersConsortiumLongitudinalStudy,Whydidyouparticipateinthestudiesandhowwasthe
experience?A:Myparentsencouragedmetojointhestudies.TheytoldmeitwouldhelpdoctorslearnmoreaboutOsteogenesisImperfecta,sotheycouldhelpothers.Theexperiencehasbeeneasyandpainless-itjusttooksometime.Butitiswellplanned.Q:Whatdoesresearchmeantoyou?A:Themoreyouknow,thebetter.Knowledgeispower.Q:Wheredoyouwanttheresearchtogo?A:OfcourseI'dloveacureforOI!Q:Whatdoyouexpecttoseefromthenewconsortium?A:SincetherearemorecitiesinvolvedtherewillbemanymorepeoplewithOIinthestudy.Andwithmorepeople,thedoctorswillhavemoreinformationtostudy.
Andersson’sloveofanimalsinspiredthestoryofMissy,ahomelesslionadoptedbyafamilyinIllinois.
TheOIF–AValuableBrittleBoneDisordersPartner
AstheBrittleBoneDisordersConsortiumbecomesmoreandmoreactivetheparticipationoftheOsteogenesisImperfectaFoundationbecomesmoreimportant.Asyoualreadyknow,oneimpressivefeatureoftheRareDiseasesClinicalResearchnetworkisthedirectinvolvementofsupportingpatientadvocacygroupsinnetworkoperations,activitiesandstrategies.Eachconsortiuminthenetworkincludesrelevantpatientadvocacygroupsintheconsortiummembershipandactivities.TheOIFoundationistheleadingpatientadvocacyorganizationservingpeoplewithOIandmedicalprofessionals.AsastrongBBDCpartnertheOIFoundationhastakentheleadroleofpreparingandprovidingeducationalmaterialsfor
medicalprofessionalsthatmayormaynotseealargenumberofpeoplewithOI.It’scriticalthatmedicalprofessionalshavetheresourcestheyneedwhentreatingapersonwithararedisorderandtheOIFoundationisprovidingthatlinkbetweenphysicianandthepersonwithOI.
FormoreinformationabouttheFoundationpleasevisitwww.oif.org.
Advocacy Partner byTracyHart,CEOOsteogenesisImperfectaFoundation
Drs.DiMeglio,Tosi,andNagamaniattheInterdisciplinarySymposiumonOsteoporosis(ISO)2016MeetingsponsoredbytheNationalOsteoporosisFoundation
A message from the BBD Consortium’s 1st Participant byAndersson
Anderssonistheauthorof“Missy”
TITLESUBTITLE|Issue1 3
UPCOMINGEVENTS
2016 OIF National Conference Orlando, FL | July 22-24, 2016 Morethan600membersoftheOIcommunitywillcometogetherforthreedaysofspecializedsessionsonmanagingOI,freemedicalconsultationsandfunsocialeventsforattendeesofallages!TheentireconferencewilltakeplaceattheWaltDisneyWorldSwan&DolphinResort.
The American Society of Bone and Mineral Research Annual Meeting and Exhibit Atlanta, GA | September 16-19, 2016AspartoftheAncillaryProgram,theOIFoundationissponsoringtheRareBoneDiseaseWorkingGroupmeetingatthe2016ASBMRAnnualMeeting.TheOIFwillalsohaveaboothintheexhibithall.Moreinformationwillbereleasedasitbecomesavailable.
FUNFACTS
3 billion Theaveragehumanheartbeatsmorethanthreebilliontimesinaveragelifespan.–NationalGeographic
8% Yourbloodmakesupabout8%ofyourbodyweight.–NationalGeographic
300 Ababy’sskeletonconsistsofasmanyas300bones.Overtime,manyofthosebonesfusetogether.–Pbs.org
Myinitialinterestinosteogenesisimperfecta(OI)wasspurredbymycolleagueandmentor,Dr.BrendanLee.HisvisionwastoadvancecareforchildrenwithOIandotherskeletaldysplasiasbyestablishingamultidisciplinaryclinicatourinstitution.HeaskedmeandourcolleagueCarlosBacinotojoinwithhimasattendingphysiciansfortheclinic.Dr.FrancisGlorieuxhadjustpublishedhisresultsofpamidronatetherapyforchildrenwithOIandwerealizedtheneedtoensurethatourpatientshadavailabletothemtheseemergingtherapies.
IthastrulybeenamazingtoseethetransformationinpatientcareandresearchinOIoverthepast15years.InowhaveteenagepatientswithOItypeIVwhohavereceivedtreatmentfrombirthandarenowlivingtheirlivesfully;Ihaveonegirlwhotakescontactkaratelessonsandaboywhoplayscontactfootball(certainlynotatmyrecommendationbuttheyarehavingfunanditisamazingtosee!).Additionally,manychildrenwithOItypesIII&IVareabletowalkindependentlyathomeorschoolthroughmedicalandsurgicaladvancesthataretrulyimprovingtheirqualityoflife.
Aboutsevenyearsago,IwasfortunatetobeofferedtheopportunitytoparticipateinfurtheradvancingcareandtreatmentsforOI,incollaborationwiththeOIFoundation(OIF)andDr.PeterByers.WedevelopedalongitudinalstudyofOI(theLinkedClinicalResearchCentersmulti-sitestudyofOI)thatultimatelyenrolledover550peoplewithallformsofOI.Throughresearchonhowthingschangedyear-to-yearforpeoplewithOI,wewereabletoimproveourunderstandingofbrittlebonediseaseandthishasresultedinmultiplepublicationsofnewdiscoveriesandafullerunderstandingofthechallengespeoplewithOIface.BaseduponthesuccessoftheOIF-fundedlongitudinalstudy,wewereawardedaprestigiousgrantfromtheNationalInstitutesofHealthtoestablishaBrittleBoneDiseasesRareDiseaseClinicalResearchConsortium(BBD-RDCRC).Thismulti-sitestudywillcontinueonthelongitudinalstudy,specificallyfocusingonthefollowingissues:
• Scoliosis
• Dental&craniofacialhealth
• Pregnancy
• Qualityoflife• Vertebralcompressionfracturesin
typeIOI
• Developingnewbiologicalmarkersfordiagnosisandthemonitoringofnewtreatments
• ResearchonnewmedicationstotreatOI
ItisreallyincredibletoreflectuponhowfarwehavecomeinthepastdecadeandIknowthatthisisjustthebeginningofatransformationtonewtherapiesforOI.ItisincredibletohavetheopportunitytobepartofthisrevolutionandIamincrediblygratefulforallthatmypatientsandtheirparentshavetaughtmeaboutOI.WewouldnotbewherewearetodaywithoutyourparticipationaswellasthecommitmentoftheOIFandthecollaborationofallmycolleagues.Thankyouforguidingmeonthisexcitingjourney.
V. Reid Sutton, MD Professor Department of Molecular & Human Genetics
Meet the Doctors V.ReidSutton,M.D.
Dr.SuttonattheKlebergGeneticsClinicatTexasChildren’sHospital
TITLESUBTITLE|Issue1 4
Current:
NaturalHistoryStudy(BBD7701)
Thepurposeofthisnaturalhistorystudyistoperformalong-termfollow-upofalargegroupofpeoplewithosteogenesisimperfecta(OI).Wewillcollectinformationincluding:
§ medicalhistory§ numberofbrokenbones§ surgeriesdone§ medicationstaken§ abilitytowalk§ pain§ lungfunctionandbreathing§ hearing§ bonemineraldensity
TheoverallgoalistoimprovethehealthandqualityoflifeofpeoplewithOI.Wewillaskyoucomeinforyearlystudyvisitsforatleast5years.
MoreInformation
ContactRegistry
TheRareDiseasesClinicalResearchNetwork(RDCRN)BrittleBoneDisordersConsortium(BBD)ContactRegistryisawayforpatientswithbrittlebonedisordersandtheirfamilymemberstolearnaboutBBDresearchstudiestheymaybeabletojoin.Contributetoknowledgeaboutrarediseasesbyansweringquestionsaboutyourself,yourhealth,andyourqualityoflife.
MoreInformation
BiomarkerStudy
Thepurposeofthislaboratorystudyistodevelopanon-invasivetesttodetermineOIsubtype.
WewillcollecturinesamplesandlookatvariousOIbiomarkersinurine.
MoreInformation
Upcoming:
DentalCraniofacialFeaturesofOI(BBD7704)
ThepurposeofthisstudyistofindoutmoreaboutthefacialanddentalstructuresofindividualswithOI.YoumustbeenrolledintheLongitudinalstudytobeeligibleforthisstudy.WewillperformaconebeamCTofyourjawandcorrelatethephysicalfindingswithyourgeneticfindings.
PregnancySurvey(BBD7705)
ThepurposeofthisstudyistolearnmoreaboutthecourseofpregnancyandbirthingoutcomesinwomenwithOI.AllwomenwithOIareeligibletotakethisonlinesurvey.WewillusethisdatatocreateamoreextensiveclinicalstudytodetermineifbonedensitychangesduringandafterpregnancyinwomenwithOI.
PROMISstudytool(BBD7702)
ThePROMIStoolisaself-reportingon-linesurveyallowingindividualswithOItoreporttheirqualityoflife.Weplantocomparetheself-reportingresultswiththeclinicaldatacollectedintheLongitudinalstudytovalidatethePROMIStool.
DrugTherapyTrial(BBD7706)
ThisclinicaltrialwillhelpusdetermineifanewdrugishelpfulinthetreatmentofOI.Thefirstphaseofthistrialwillfocusondrugsafetyandtolerability.WewillberecruitingandenrollingadultswithsevereOI.
Youwillcometoaparticipatingclinicalcenterforaninfusion(s)ofFresolimumab.Youwillbeaskedtoprovidebloodsamplestodeterminethesafetyprofileofthedrugoverthecourseof6-12months.Wewilllookatyourbonedensityandqualityoflifetodetermineifthesefeatureschangewhileyouareonthestudymedication.
HowtoParticipate:
Usethefollowinglinks:
ParticipatingClinicalCenters
GetInvolved
ClinicalTrials.gov
OsteogenesisImperfectaFoundation
Publications:
PMID:26426884PMCID:PMC4818203GenetMed.2015Oct1.doi:10.1038/gim.2015.131.Cesareandeliveryisnotassociatedwithdecreasedat-birthfractureratesinosteogenesisimperfecta.
BellurS1,JainM1,CuthbertsonD2,KrakowD3,4,5,ShapiroJR6,SteinerRD7,8,9,SmithPA10,BoberMB11,HartT12,KrischerJ2,MullinsM1,ByersPH13,14,PepinM13,14,DurigovaM15,GlorieuxFH15,RauchF15,SuttonVR1,16,LeeB1,16;MembersoftheBBDConsortium,NagamaniSC1,16.DescriptionOsteogenesisimperfecta(OI)isaconnectivetissuedisorderthatpredisposestorecurrentfracturesandbonedeformities.SevereformsofOIarecharacterizedbyinuterofracturesandthemodeofdeliverythatwouldbesafestforthefetusinsuchsituationsisnotknown.Inastudyinvolving540patientswithOI,researchersoftheBrittleBoneDisordersConsortiumfoundthatcesareandeliverywasnotassociatedwithadecreaseintheat-birthfractureratesinOI.Thisstudyprovidedevidence-basedanswerstoaquestionrelevantfortheclinicalcareofindividualslivingwithOI.
Clinical Research Studies